Physician profile
Lindsay Greer Frazier
NPI 1063749992
$139,936.99
in general payments reported to CMS, 2019-2025
28 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39K · 2022: $18K · 2023: $27K · 2024: $21K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Travel and Lodging: $18K · Food and Beverage: $8,896 · Consulting Fee: $5,072 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,396.00 |
| Travel and Lodging | $18,011.56 |
| Food and Beverage | $8,896.05 |
| Consulting Fee | $5,072.00 |
| Education | $180.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $70,244.30 | 2021-2025 | Dupixent |
| Genzyme Corporation | $59,021.43 | 2021-2025 | |
| Janssen Biotech, INC. | $1,782.55 | 2021-2025 | Tremfya, Simponi, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,767.91 | 2021-2024 | Cabtreo, Jublia, Arazlo |
| Abbvie INC. | $1,255.29 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,229.27 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,076.33 | 2022-2025 | Sotyktu |
| Revance Therapeutics, INC. | $549.14 | 2024-2025 | Daxxify |
| Pfizer INC. | $473.47 | 2021-2025 | |
| Galderma Laboratories, L.P. | $428.62 | 2022-2025 | Aklief, Epsolay, Nemluvio |
| Arcutis Biotherapeutics, INC. | $422.91 | 2023-2025 | Zoryve |
| Ucb, INC. | $240.72 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $200.32 | 2023-2024 | Vtama |
| Leo Pharma INC. | $178.43 | 2021-2025 | Adbry |
| Allergan, INC. | $170.99 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $168.67 | 2021-2025 | Winlevi, Absorica Ld |
| Incyte Corporation | $148.58 | 2022-2025 | Opzelura |
| Amgen INC. | $131.38 | 2023-2025 | Otezla, Otezla |
| Almirall LLC | $95.08 | 2021-2024 | Seysara, Klisyri |
| Mayne Pharma Commercial LLC | $60.62 | 2023 | |
| Lilly USA, LLC | $59.18 | 2022-2023 | Taltz, Olumiant |
| Vyne Pharmaceuticals INC. | $56.29 | 2021 | |
| Organogenesis INC. | $37.78 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $37.34 | 2022-2024 | Dupixent |
| Organon LLC | $32.62 | 2025 | Vtama |
| Kyowa Kirin, INC. | $26.44 | 2025 | |
| Merz North America, INC. | $22.56 | 2025 | |
| Medimetriks Pharmaceuticals, INC. | $18.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Frazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.